Relmada Therapeutics Inc (RLMD) Stock Price, Quote & News

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 629 1376

Website: www.relmada.com

Address:

2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States

DonCorleone77 Aug. 8 at 1:26 PM

$RLMD Information regarding Mizuho analyst note on RLMD issued today: https://x.com/CorleoneDon77/status/1953800493999825166 cc: @RonIsWrong

0 · Reply

Fremo80 Aug. 8 at 6:24 AM

$XFOR Anyone here Watch or Trade $RLMD ??? if so Thoughts after earnings yest??

0 · Reply

Gmebe Aug. 7 at 8:40 PM

$RLMD All im going to say here is... The company has less than 6 months to gain compliance and has less than 1 year of finance left with massive accrued debt. The only catalyst it has is BEYOND a year. Its 18months out which means any stock price rise on anticipated results is 12-14 months out. Over 3 years, it has gone from 75% institutional ownership to just 21%. Get out whilst you still can and dont hold it for too long, like I did. Follow the smart money. If anyone can counter my argument, believe me Im all for it.

1 · Reply

RebelWithoutAPause777 Aug. 6 at 3:08 AM

$RLMD Stick a fork in it, it's finished. Will hit all-time lows after the coming "earnings report." The entire North American market is in for some serious trouble once the effects of tariffs are priced in on both sides of the border. Trump is either insane beyond comprehension or purposely trying to send America into the stone age, or both.

2 · Reply

VictorMason Aug. 4 at 11:31 PM

$RLMD anyone who wants to see my 3 page list of complaints against RLMD send me a PM and identify yourself

1 · Reply

RiskCPremium Aug. 4 at 7:44 PM

$RLMD Q2-2025 update of NDV-01 phase-2 trial data is very critical. If NDV-01 phase-2 trial data shows comparable level of efficacy as seen in the April 28 AUA presentation, and if there is any favorable feedback from FDA vis-a-vis phase-3 pivotal trial design, then the logical next step is that Dr. Raj Pruthi, current CMO will replace Traversa Sergio, Inturrisi and Manfredi's consiglierre. I believe Dr. Raj Pruthi's resignation from $ENGN and taking CMO job at $RLMD was conditional on that, he would be an excellent CEO and steward of $RLMD/NDV-01. Dr Pruthi will be able to promote co-operation with FDA, urologist community, regain the trust of investors and analysts, and secure funding to run the trial. So far NDV-01 looks to be the most efficacious combo for NMIBC chemo drug when compared against $URGN's recently approved ZUSDURI and J&J's tar-200 (July 17, 2025 received Priority Review status for already filed NDA). Trigone Pharma, please kick some butts, rescue you and $RLMD.

0 · Reply

VictorMason Jul. 24 at 1:59 PM

$RLMD $RLMD Any word from Jeffries about how RLMD screwed up the relight, didn't finish recruitment and just abandoned REL-1017 ? "Heres RLMD jeffries report of Wednesday of the 19th? Important Execution Period Ahead of Key Phase III Depression Data in H2:24 Big Picture: We'd argue REL-1017's efficacy/safety is arguably less of a risk at this juncture. The drug has shown a consistent and tight Day 28 MADRS efficacy benefit of -15-17 points (absolute) across two large Phase III RELIANCE studies and a separate OLE study in de-novo MDD patients - which (1) looks comparable to (or better than) the efficacy produced by approved MDD drugs and (2) could even increase by another 2 points in the two new Phase IIIs (RELIANCE-2, RELIGHT), now with COVID subsiding. Instead, we think the prior Phase IIIs were hurt by a high placebo response (due to 2-4 outlier sites), as we see a high -13-14 MADRS sore at Day 28 (whereas the industry norm is closer to -8-12)

1 · Reply

RiskCPremium Jul. 23 at 9:12 PM

$RLMD On July 22, 2025, Nasdaq notified the Company that it had approved the Company’s application to transfer its listing to the Nasdaq Capital Market. The Company’s securities will be transferred to the Nasdaq Capital Market at the opening of business on July 24, 2025. Nasdaq also approved a 180-day extension, or until January 19, 2026 (the “Compliance Period”), to regain compliance with the minimum bid price in accordance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s common stock must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to the expiration of the Compliance Period.

1 · Reply

RiskCPremium Jul. 23 at 9:10 PM

0 · Reply

RiskCPremium Jul. 23 at 9:10 PM

$RLMD

0 · Reply

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 22 hours ago

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Jul 31, 2025, 7:00 AM EDT - 8 days ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 15, 2025, 8:00 AM EDT - 24 days ago

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 9, 2025, 8:00 AM EDT - 4 weeks ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Jun 17, 2025, 7:00 AM EDT - 7 weeks ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

May 12, 2025, 10:02 PM EDT - 3 months ago

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 3 months ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:30 AM EDT - 3 months ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 28, 2025, 1:38 PM EDT - 3 months ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 3 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 24, 2025, 8:00 AM EDT - 3 months ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 14, 2025, 7:30 AM EDT - 4 months ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Mar 27, 2025, 8:07 PM EDT - 4 months ago

Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 4 months ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 26, 2025, 9:00 AM EDT - 4 months ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 25, 2025, 7:30 AM EDT - 4 months ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Feb 6, 2025, 7:30 AM EST - 6 months ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Dec 9, 2024, 8:11 AM EST - 8 months ago

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 7:30 AM EST - 8 months ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 4, 2024, 2:02 PM EST - 8 months ago

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Dec 4, 2024, 8:00 AM EST - 8 months ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 7:30 AM EST - 8 months ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Nov 21, 2024, 1:34 PM EST - 9 months ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 14, 2024, 7:30 AM EST - 9 months ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 10, 2024, 9:39 AM EST - 9 months ago

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:32 PM EST - 9 months ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:30 PM EST - 9 months ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Aug 9, 2024, 6:25 AM EDT - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 9:45 AM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue

Jul 23, 2024, 3:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Impacted Investors Urged To Engage In Dialogue

Jul 22, 2024, 11:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Encourages Impacted Investors To Initiate Dialogue

Jul 19, 2024, 5:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Breaches And Impacted Investors Are Encouraged To Initiate Dialogues

Jul 18, 2024, 5:15 PM EDT - 1 year ago

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Violations And Urges Affected Investors To Start Conversations

Jul 17, 2024, 3:30 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Examination For Possible Securities Breaches By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate Dialogues

Jul 16, 2024, 3:45 PM EDT - 1 year ago

The Schall Law Firm Encourages Affected Investors To Start Conversation, Relmada Therapeutics Inc Is Under Scrutiny For Potential Securities Breaches

Jul 15, 2024, 3:15 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Urging Impacted Investors To Initiate Dialogue

Jul 13, 2024, 7:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Probe By The Schall Law Firm For Possible Securities Breaches Urges Affected Investors To Start Conversation

Jul 12, 2024, 6:45 PM EDT - 1 year ago

Potential Securities Violations By Relmada Therapeutics Inc Are Under Investigation By The Schall Law Firm Encouraging Impacted Investors To Initiate Dialogue

Jul 11, 2024, 2:15 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Scrutiny By The Schall Law Firm For Potential Securities Breaches Urging Affected Investors To Initiate Conversation

Jul 10, 2024, 2:30 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Violations And Impacted Investors Are Urged To Establish Dialogue

Jul 9, 2024, 3:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Being Probed By The Schall Law Firm For Potential Securities Breaches And Affected Investors Are Encouraged To Set Up Communication

Jul 8, 2024, 1:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Violations And Impacted Investors Are Urged To Establish Communication

Jul 7, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Begins Probe Into Relmada Therapeutics Inc For Suspected Securities Violations And Promotes Investors With Losses To Get In Touch

Jul 6, 2024, 11:00 AM EDT - 1 year ago

Investigation Into Possible Securities Infringements By Relmada Therapeutics Inc Is Being Conducted By The Schall Law Firm And It Invites Affected Investors To Reach Out

Jul 5, 2024, 4:00 PM EDT - 1 year ago

The Schall Law Firm Initiates Examination Into Relmada Therapeutics Inc For Potential Securities Breaches And Encourages Impacted Investors To Establish Contact

Jul 3, 2024, 12:30 PM EDT - 1 year ago

The Schall Law Firm Investigates Relmada Therapeutics Inc For Potential Securities Breaches And Encourages Impacted Investors To Connect

Jul 2, 2024, 3:30 PM EDT - 1 year ago

The Schall Law Firm Probes Relmada Therapeutics Inc For Possible Securities Violations And Urges Affected Investors To Contact

DonCorleone77 Aug. 8 at 1:26 PM

$RLMD Information regarding Mizuho analyst note on RLMD issued today: https://x.com/CorleoneDon77/status/1953800493999825166 cc: @RonIsWrong

0 · Reply

Fremo80 Aug. 8 at 6:24 AM

$XFOR Anyone here Watch or Trade $RLMD ??? if so Thoughts after earnings yest??

0 · Reply

Gmebe Aug. 7 at 8:40 PM

1 · Reply

RebelWithoutAPause777 Aug. 6 at 3:08 AM

2 · Reply

VictorMason Aug. 4 at 11:31 PM

$RLMD anyone who wants to see my 3 page list of complaints against RLMD send me a PM and identify yourself

1 · Reply

RiskCPremium Aug. 4 at 7:44 PM

0 · Reply

VictorMason Jul. 24 at 1:59 PM

1 · Reply

RiskCPremium Jul. 23 at 9:12 PM

1 · Reply

RiskCPremium Jul. 23 at 9:10 PM

0 · Reply

RiskCPremium Jul. 23 at 9:10 PM

$RLMD

0 · Reply

RiskCPremium Jul. 23 at 9:10 PM

$RLMD https://www.relmada.com/for-investors/sec-filings/content/0001213900-25-066995/0001213900-25-066995.pdf On July 22, 2025, Nasdaq notified the Company that it had approved the Company’s application to transfer its listing to the Nasdaq Capital Market. The Company’s securities will be transferred to the Nasdaq Capital Market at the opening of business on July 24, 2025. Nasdaq also approved a 180-day extension, or until January 19, 2026 (the “Compliance Period”), to regain compliance with the minimum bid price in accordance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s common stock must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to the expiration of the Compliance Period.

0 · Reply

RiskCPremium Jul. 23 at 9:09 PM

0 · Reply

BigSqueezeComing Jul. 22 at 8:53 AM

$RLMD pm gapper . road to $1. next stop .75

0 · Reply

Gmebe Jul. 21 at 5:08 PM

$RLMD did i miss something? Today is the last day for nasdaq compliance before it gets delisted. It gets delisted if they dont get an extension....

0 · Reply

RiskCPremium Jul. 19 at 9:21 PM

$RLMD Sergio Traversa, Manfredi, Inturrisi, and rest of the Exec team & BOD members are running a fraud scheme to defraud the existing RLMD shareholders. After the key man, Sergio released the Rel-1017 to Manfredi, Manfredi hired his own patent lawyers to get a new patent/patent extension for Rel-1017 so that they can set up a new company or merge with an existing one like DIMERx. Sergio Traversa is the ruthless face of the group. I am astounded by the fact that Sergio stated in Jefferies' London Health Conf - Nov 19-21 2024 that pre and post covid delta of Rel-1017 - placebo vs Rel-1017 was close to 6, and 2 weeks later drug failed, no further followup analysis. Now he released the drug to Manfredi. Sergio Traversa and each an̈d everyone of his enablers should be brought to justice for defrauding RLMD shareholders.

0 · Reply

VictorMason Jul. 17 at 3:33 PM

$RLMD at least you can say RLMD isn't 'overbought' Skating up to the edge

1 · Reply

Cashflow62 Jul. 16 at 2:18 PM

$RLMD Bold prediction here, going to a buck next 30-45 days.

1 · Reply

BigSqueezeComing Jul. 15 at 12:05 PM

$RLMD Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 By Relmada Therapeutics | July 15, 2025, 8:00 AM

0 · Reply

VictorMason Jul. 11 at 1:23 PM

$RLMD after $600MM spent they just abandon REL-1017? didn't complete the recruitment of vetted candidates for Relight placebo arm do over of the phase 3. But trust these guys to find new projects to develop. No big expense payment coming up, why abandon and not sell it to someone who knows how to control for placebo effect. Watch what Inturisi and Manfrefi do with it, bet Sergio will be involved w a bigger %

1 · Reply

1972Camaro Jul. 10 at 12:33 PM

$NUVB here are two interesting candidates with insider buying I am watching, $MBRX $RLMD

2 · Reply

Gmebe Jul. 8 at 9:05 PM

$RLMD 14 days left to get compliance. Extension is probably going to be requested id guess as its a bit late to do an RS.

0 · Reply

VictorMason Jul. 3 at 4:02 PM

$RLMD interesting new report, but misleading on some of their 6 critical points. 'Earnings' and revenue going down - they have neither, only losses ($600MM so far to develop the abandoned REL-1017) Insider buying isnt all that much $$, they took millions in cheap stock options. They can always sell the tax losses ($3/ share?) And sell REL1017 phase 3 to someone who knows how to handle a placebo effect https://share.google/seOmgMXD1pM7dxjfx

0 · Reply

Market Cap	19.88M
Revenue (ttm)	0.00
Net Income (ttm)	-79.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	71,392
Avg Vol	332,386
Day's Range	N/A - N/A
Shares Out	33.19M
Stochastic %K	29%
Beta	0.66
Analysts	Hold
Price Target	$0.87